Compare Becton Dickinson and Co (BDX) vs Wahed FTSE USA Shariah ETF (HLAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Wahed FTSE USA Shariah ETF — how do they compare? Becton Dickinson and Co trades at $149.95 (market cap $41.51B), while Wahed FTSE USA Shariah ETF trades at $71.69. The key difference: Becton Dickinson and Co pays a 2.79% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | HLAL | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.39 | $73.60 |
52-Week Low | $135.49 | $53.83 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
HLAL trades at $71.08, down 1.34% today. The technical outlook is bullish based on moving averages, with oscillators neutral. Key support sits at $71 and resistance at $72. A dividend of $0.02 is scheduled for June 2026. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The stock's near-term trajectory hinges on upcoming earnings and broader market trends. Risks include lack of recent financial disclosures and potential volatility. Upside depends on positive fundamental developments and sustained technical momentum amid neutral sentiment indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →
